Journal of Neuro-Oncology

, Volume 83, Issue 1, pp 61–70

Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience

  • H. Christopher Lawson
  • Prakash Sampath
  • Eileen Bohan
  • Michael C. Park
  • Namath Hussain
  • Alessandro Olivi
  • Jon Weingart
  • Lawrence Kleinberg
  • Henry Brem
Clinical–Patient Studies

DOI: 10.1007/s11060-006-9303-1

Cite this article as:
Lawson, H.C., Sampath, P., Bohan, E. et al. J Neurooncol (2007) 83: 61. doi:10.1007/s11060-006-9303-1

Abstract

Malignant gliomas are very difficult neoplasms for clinicians to treat. The reason for this is multifaceted. Many treatments that are effective for systemic cancer are unable to cross the blood-brain barrier and/or have unacceptable systemic toxicities. Consequently, in recent years an effort has been placed on trying to develop innovative local treatments that bypass the blood-brain barrier and allow for direct treatment in the central nervous system (CNS)—interstitial treatment. In this paper, we present our extensive experience in using interstitial chemotherapy as a strategy to treat malignant brain tumors at a single institution (The Johns Hopkins Hospital). We provide a comprehensive summary of our preclinical work on interstitial chemotherapy at the Hunterian Neurosurgery Laboratory, reviewing data on rat, rabbit, and monkey studies. Additionally, we present our clinical experience with randomized placebo-controlled studies for the treatment of malignant gliomas. We compare survival statistics for those patients who received placebo versus Gliadel® as initial therapy (11.6 months vs. 13.9 months, respectively) and at the time of tumor recurrence (23 weeks vs. and 31 weeks, respectively). We also discuss the positive impact of local therapy in avoiding the toxicities associated with systemic treatments. Furthermore, we provide an overview of newer chemotherapeutic agents and other strategies used in interstitial treatment. Finally, we offer insight into some of the lessons we have learned from our unique perspective.

Keywords

Carmustine·Gliadel® Glioblastoma multiforme Interstitial chemotherapy Malignant glioma 

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • H. Christopher Lawson
    • 1
  • Prakash Sampath
    • 3
    • 5
  • Eileen Bohan
    • 1
  • Michael C. Park
    • 3
  • Namath Hussain
    • 4
  • Alessandro Olivi
    • 1
    • 2
  • Jon Weingart
    • 1
    • 2
  • Lawrence Kleinberg
    • 1
    • 2
  • Henry Brem
    • 1
    • 2
  1. 1.Department of Neurological SurgeryJohns Hopkins Medical InstitutionsBaltimoreUSA
  2. 2.Department of Radiation OncologyJohns Hopkins Medical InstitutionsBaltimoreUSA
  3. 3.Department of Clinical Neurosciences Program in NeurosurgeryBrown Medical School, Rhode Island HospitalProvidenceUSA
  4. 4.Department of NeurosurgeryUniversity of ArizonaTucsonUSA
  5. 5.Roger Williams HospitalProvidenceUSA